Proton beam irradiation of uveal melanomas: The first 30 years. The Weisenfeld lecture

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 11, 2006, Pages 4666-4673

  Gragoudas, Evangelos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; INTERLEUKIN 2; IODINE 125; RHODIUM; RHODIUM 106; RUTHENIUM 106; UNCLASSIFIED DRUG;

ARTICLE; CANCER CONTROL; CANCER INCIDENCE; CANCER MORTALITY; CHEMOEMBOLIZATION; CLINICAL TRIAL; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IRIS RUBEOSIS; LIVER METASTASIS; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTON RADIATION; PROTON THERAPY; RADIATION DOSE; RADIATION INJURY; REGISTER; TREATMENT INDICATION; TREATMENT PLANNING; UNITED STATES; UVEA MELANOMA; MELANOMA; RADIOISOTOPE THERAPY; UVEA TUMOR;

HUMANS; MELANOMA; RADIOISOTOPE TELETHERAPY; UVEAL NEOPLASMS;

EID: 34247095590     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0659     Document Type: Article

References (99)

1. Scotto J, Fraumeni JF Jr, Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst. 1976;56:489-491.
2. Ganley JP, Comstock GW. Benign nevi and malignant melanomas of the choroid. Am J Ophthalmol. 1973;76:19-25.
3. Augsburger JJ, Schroeder RP, Territo C, Gamel JW, Shields JA. Clinical parameters predictive of enlargement of melanocytic choroidal lesions. Br J Ophthalmol. 1989;73:911-917.
4. Butler P, Char DH, Zarbin M, Kroll S. Natural history of indeterminate pigmented choroidal tumors. Ophthalmology. 1994;101:710-716; discussion 717.
5. Shields CL, Cater J, Shields JA, Singh AD, Santos MC, Carvalho C. Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Arch Ophthalmol. 2000;118:360-364.
6. Augsburger JJ, Vrabec TR. Impact of delayed treatment in growing posterior uveal melanomas. Arch Ophthalmol. 1993;111:1382-1386.
7. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE Jr. Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol. 2003;136:47-54.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
9. Apte RS, Niederkorn JY, Mayhew E, Alizadeh H. Angiostatin produced by certain primary uveal melanoma cell lines impedes the development of liver metastases. Arch Ophthalmol. 2001;119:1805-1809.
10. Yang H, Akor C, Dithmar S, Grossniklaus HE. Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model. Mol Vis. 2004;23:987-995.
11. Packer S, Rotman M. Radiotherapy of choroidal melanoma with iodine-125. Ophthalmology. 1980;87:582-590.
12. Shields JA, Augsburger JJ, Brady LW, Day JL. Cobalt plaque therapy of posterior uveal melanomas. Ophthalmology. 1982;89:1201-1207.
13. Lommatzsch P. Beta-irradiation of choroidal melanoma with 106Ru/106Rh applicators: 16 years' experience. Arch Ophthalmol. 1983;101:713-717.
14. Finger PT, Buffa A, Mishra S, Berson A, Bosworth JL, Vikram B. Palladium 103 plaque radiotherapy for uveal melanoma: clinical experience. Ophthalmology. 1994;101:256-263.
15. Egger E, Zografos L, Munkel G, Bohringer T, Bercher L, Chamot L. Results of proton radiotherapy for uveal melanomas. Front Radiat Ther Oncol. 1997;30:111-122.
16. Castro JR, Char DH, Petti PL, et al. 15 years experience with helium ion radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 1997;39:989-996.
17. Desjardins L, Levy C, D'Hermies F, et al. Initial results of proton therapy in choroidal melanoma at the d'Orsey Center for Proton Therapy: the first 464 cases. Cancer Radiother. 1997;1:222-226.
18. Fuss M, Loredo LN, Blacharski PA, Grove RI, Slater JD. Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys. 2001;49:1053-1059.
19. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120:1665-1671.
20. Lichter AS, Lawrence TS. Recent advances in radiation oncology. N Engl J Med. 1995;332:371-379.
21. Stallard H. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol. 1966;50:147-155.
22. Stallard HB. Malignant melanoblastoma of the choroid. Bibl Ophthalmol. 1968;75:16-38.
23. MacFaul P, Bedford M. Ocular complications after therapeutic irradiation. Br J Ophthalmol. 1970;54:237-247.
24. Kleineidam M, Guthoff R, Bentzen SM. Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques. Radiother Oncol. 1993;28:148-156.
25. Packer S, Rotman M, Salanitro P. Iodine-125 irradiation of choroidal melanoma: clinical experience. Ophthalmology. 1984;91:1700-1708.
26. 125I plaque brachytherapy for ocular melanoma, Int J Radiat Oncol Biol Phys. 2005;63:101-108.
27. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;109:2197-2206.
28. Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol. 1999;127:579-589.
29. Char DH, Kroll S, Phillips TL, Quivey JM. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology. 2002;109:1850-1854.
30. Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys. 2005;62:1405-1411.
31. Egger E, Schalenbourg A, Zografos L, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2001;51:138-147.
32. Gragoudas ES, Goitein M, Koehler A, et al. Proton irradiation of choroidal melanomas: preliminary results. Arch Ophthalmol. 1978;96:1583-1591.
33. Gragoudas ES, Goitein M, Verhey L, et al. Proton beam irradiation of uveal melanomas: results of 5 1/2-year study. Arch Ophthalmol. 1982;100:928-934.
34. Gragoudas ES, Seddon J, Goitein M, et al. Current results of proton beam irradiation of uveal melanomas. Ophthalmology. 1985;92:284-291.
35. Char DH, Saunders W, Castro JR, et al. Helium ion therapy for choroidal melanoma. Ophthalmology. 1983;90:1219-1225.
36. Mueller AJ, Talies S, Schaller UC, Horstmann G, Wowra B, Kampik A. Stereotactic radiosurgery of large uveal melanomas with the gamma-knife. Ophthalmology. 2000;107:1381-1387; discussion 1387-1388.
37. Haas A, Pinter O, Papaefthymiou G, et al. Incidence of radiation retinopathy after high-dosage single-fraction gamma knife radiosurgery for choroidal melanoma. Ophthalmology. 2002;109:909-913.
38. Char DH, Kroll SM, Castro J. Ten-year follow-up of helium ion therapy for uveal melanoma. Am J Ophthalmol. 1998;125:81-89.
39. Gragoudas ES, Goitein M, Koehler AM, et al. Proton irradiation of small choroidal malignant melanomas. Am J Ophthalmol. 1977;83:665-673.
40. Glynn RJ, Seddon JM, Gragoudas ES, Egan KM, Hart LJ. Evaluation of tumor regression and other prognostic factors for early and late metastasis after proton irradiation of uveal melanoma. Ophthalmology. 1989;96:1566-1573.
41. Gragoudas ES, Egan K, Seddon J, Walsh S, Munzenrider J. Intraocular recurrence of uveal melanoma after proton beam irradiation. Ophthalmology. 1992;99:760-766.
42. Gragoudas ES, Seddon JM, Egan K, et al. Metastasis from uveal melanoma after proton beam irradiation. Ophthalmology. 1988;95:992-999.
43. Gragoudas ES, Egan K, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383-390.
44. Li W, Gragoudas ES, Egan KM. Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol. 2000;118:1066-1070.
45. Seddon JM, Gragoudas ES, Polivogianis L, et al. Visual outcome after proton beam irradiation of uveal melanoma. Ophthalmology. 1986;93:666-674.
46. Seddon JM, Gragoudas ES, Egan KM, et al. Uveal melanomas near the optic disc or fovea: visual results after proton beam irradiation. Ophthalmology. 1987;94:354-361.
47. Gragoudas ES, Egan KM, Walsh SM, Regan S, Munzenrider JE, Taratuta V. Lens changes after proton beam irradiation for uveal melanoma. Am J Ophthalmol. 1995;119:157-164.
48. Park SS, Walsh SM, Gragoudas ES. Visual-field deficits associated with proton beam irradiation for parapapillary choroidal melanoma. Ophthalmology. 1996;103:110-116.
49. Seddon JM, Gragoudas ES, Albert DM, Hsieh CC, Polivogianis L, Friedenberg GR. Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am J Ophthalmol. 1985;99:282-290.
50. Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology. 1990;97:769-777.
51. Wang X, Egan KM, Gragoudas ES, Kelsey KT. Constitutional alterations in p16 in patients with uveal melanoma. Melanoma Res. 1996;6:405-410.
52. Sinilnikova OM, Egan KM, Quinn JL, et al. Germline brca2 sequence variants in patients with ocular melanoma. Int J Cancer. 1999;82:325-328.
53. Seddon J, Gragoudas E, Egan K, Polivogianis L, Finn S, Albert D. Standardized data collection and coding in eye disease epidemiology: the uveal melanoma data system. Ophthalmic Surg. 1991;22:127-136.
54. Egan KM, Gragoudas ES, Seddon J, Walsh S. Smoking and the risk of early metastases from uveal melanoma. Ophthalmology. 1992;99:537-541.
55. Egan KM, Walsh SM, Seddon JM, Gragoudas ES. An evaluation of the influence of reproductive factors on the risk of metastases from uveal melanoma. Ophthalmology. 1993;100:1160-1166.
56. Regan S, Judge H, Gragoudas ES, Egan KM. Iris color as a prognostic factor in ocular melanoma. Arch Ophthalmol. 1999;117:811-814.
57. Wilson R. Radiological use of fast protons. Radiology. 1946;47:487-491.
58. Lawrence JH. Proton irradiation of the pituitary. Cancer. 1957;10:795-798.
59. Koehler A, Schneider R, Sisterson J. Range modulators for protons and heavy ions. Nucl Instrum Methods. 1975;131:437-440.
60. Suit HD, Gotein M, Tepper J, Koehler A, Schmidt R, Schneider R. Exploratory study of proton radiation therapy using large field techniques and fractionated dose schedules. Cancer. 1975;35:1646-1657.
61. Gragoudas ES, Goitein M, Seddon JM, et al. Preliminary results of proton beam irradiation of macular and paramacular melanomas. Br J Ophthalmol. 1984;68:479-485.
62. Suit H. The Gray Lecture 2001: coming technical advances in radiation oncology. Int J Radiat Oncol Biol Phys. 2002;53:798-809.
63. Saornil MA, Egan KM, Gragoudas ES, Seddon JM, Walsh SM, Albert DM. Histopathology of proton beam-irradiated vs enucleated uveal melanomas. Arch Ophthalmol. 1992;110:1112-1118.
64. Li W, Judge H, Gragoudas ES, Seddon JM, Egan KM. Patterns of tumor initiation in choroidal melanoma. Cancer Res. 2000;60:3757-3760.
65. Constable IJ, Koehler AM. Experimental ocular irradiation with accelerated protons. Invest Ophthalmol. 1974;13:280-287.
66. Gragoudas ES, Zakov NZ, Albert DM, Constable IJ. Long-term observations of proton-irradiated monkey eyes. Arch Ophthalmol. 1979;97:2184-2191.
67. Gragoudas ES, Goitein M, Verhey L, Munzenrider J, Suit H, Koehler A. Proton beam irradiation: an alternative to enucleation for intraocular melanomas. Ophthalmology. 1980;87:571-581.
68. Goitein M, Miller T. Planning proton therapy of the eye. Med Phys. 1983;10:275-283.
69. Wilkes SR, Gragoudas ES. Regression patterns of uveal melanoma after proton beam irradiation. Ophthalmology. 1982;89:840-844.
70. Gragoudas ES, Egan KM, Saornil MA, Walsh SM, Albert DM, Seddon JM. The time course of irradiation changes in proton beam-treated uveal melanomas. Ophthalmology. 1993;100:1555-1559; discussion 1560.
71. Kodjikian L, Roy P, Rouberol F, et al. Survival after proton beam irradiation of uveal melanomas. Am J Ophthalmol. 2004;137:1002-1010.
72. Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc. 2002;100:43-48; discussion 48-49.
73. Marucci L, Lane AM, Li W, et al. Conservation treatment of the eye: conformal proton reirradiation for recurrent uveal melanoma, Int J Radiat Oncol Biol Phys. 2006;64:1018-1022.
74. Courdi A, Caujolle JP, Grange JD, et al. Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys. 1999;45:5-11.
75. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969-982.
76. Gragoudas ES, Lane AM. Uveal melanoma: proton beam irradiation. Ophthalmol Clin North Am. 2005;18:111-118, ix.
77. McLean IW, Foster W, Zimmerman L. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol. 1982;13:123-132.
78. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol. 1983;101:1894-1899.
79. Egan KM, Ryan LM, Gragoudas ES. Survival implications of enucleation after definitive radiotherapy for choroidal melanoma: an example of regression on time-dependent covariates. Arch Ophthalmol. 1998;116:366-370.
80. Cochran AJ, Elashoff D, Morton DL, Elashoff R. Individualized prognosis for melanoma patients. Hum Pathol. 2000;31:327-331.
81. Hawkins BS, Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004;138:936-951.
82. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639-1643.
83. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: The Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004;22:2438-2444.
84. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23:8076-8080.
85. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665-1670.
86. Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97:465-475.
87. Alexander HR Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:6343-6349.
88. Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol. 1998;21:568-572.
89. Proebstle TM, Scheibenbogen C, Steny W, Keilholz U. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma. Eur J Cancer. 1996;32A:1530-1533.
90. Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89:1561-1568.
91. Hsueh EC, Essner R, Foshag LJ, Ye X, Wang HJ, Morton DL. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer. 2004;100:122-129.
92. Egan KM, Gragoudas ES, Seddon JM, et al. The risk of enucleation after proton beam irradiation of uveal melanoma. Ophthalmology. 1989;96:1377-1382; discussion 1382-1383.
93. Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;55:867-880.
94. Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular radiation. Ophthalmology. 1999;106:1571-1577; discussion 1577-1578.
95. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Phys. 1994;30:765-773.
96. Daftari IK, Char DH, Verhey LJ, et al. Anterior segement sparing to reduce charged particle radiotherapy complications in uveal melanoma. Int J Rad Oncol Biol Phys. 1997;39:997-1010.
97. Foss AJ, Whelehan I, Hungerford JL, et al. Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol. 1997;81:748-754.
98. Gragoudas ES, Egan KM, Arrigg PG, Seddon JM, Glynn RJ, Munzenrider JE. Cataract extraction after proton beam irradiation for malignant melanoma of the eye. Arch Ophthalmol. 1992;110:475-479.
99. Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118:773-778.